[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100085463":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":11,"locations":23,"responsibleParty":37,"collaborators":11,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":11,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":11,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL",null,[13],"Drug: Salmeterol\u002Ffluticasone propionate and fluticasone propionate",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":11},"DRUG","Salmeterol\u002Ffluticasone propionate and fluticasone propionate",[9],[20],{"name":21,"affiliation":5,"role":22},"GSK Clinical Trials","STUDY_DIRECTOR",[24],{"facility":25,"status":11,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":11},"GSK Investigational Site","Manchester","Lancashire","M23 9LT","United Kingdom","UK",{"type":32,"coordinates":33},"Point",[34,35],-2.23743,53.48095,{"lat":35,"lon":34},{"type":38,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100085463","phase-4-study-of-airway-physiology-in-adults-seretide-diskus-inhaler-and-flixotide-inhaler-are-trademarks-of-gsk-croup-of-companies-100085463",false,"NCT00370591","Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.","Randomised, Double Blind, Parallel Group Study to Assess the Bronchodilative and Bronchoprotective Properties of SERETIDE DISKUS® Inhaler 50\u002F100 mcg Twice Daily vs FLIXOTIDE® Inhaler 200 mcg Twice Daily","Inclusion:\n\n* Physician documented diagnosis of asthma which has been present for at least 6 months.\n* Receiving a total daily dose of 200-500mcg\u002Fday beclomethasone dipropionate or equivalent for at least 4 weeks prior to the start of the run-in period.\n\nExclusion:\n\n* Has had 3 or more courses of oral corticosteroids in the 12 months previous to visit 1","ALL","18 Years","65 Years",{"count":50,"type":51},48,"ACTUAL","INTERVENTIONAL",[54],"PHASE4","Comparison of two asthma treatments by lung function measures.",[57],"Asthma",[59,57],"Inhaled corticosteroids","COMPLETED","2016-09-13",{"date":63,"type":64},"2016-09-15","ESTIMATED",{"date":66,"type":11},"2002-12",{"date":68,"type":51},"2004-04",{"name":5,"class":6},1]